Section Arrow
INO.NASDAQ
- Inovio Pharmaceuticals
Quotes are at least 15-min delayed:2026/04/15 09:41 EDT
Regular Hours
Last
 1.135
+0.025 (+2.25%)
Day High 
1.1395 
Prev. Close
1.11 
1-M High
1.785 
Volume 
450.17K 
Bid
1.13
Ask
1.13
Day Low
1.115 
Open
1.115 
1-M Low
1.03 
Market Cap 
90.57M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 1.22 
20-SMA 1.42 
50-SMA 1.59 
52-W High 2.9789 
52-W Low 1.03 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.81/-0.01
Enterprise Value
97.11M
Balance Sheet
Book Value Per Share
0.30
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
65.34K
Operating Revenue Per Share
0.12
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
IMMPImmutep Limited0.8799+0.5651+179.51%-- 
LIMNLiminatus Pharma Inc0.196+0.0162+9.01%-- 
ALLOAllogene Therapeutics1.885-0.395-17.32%-- 
LNAILunai Bioworks Inc.0.2984-0.0404-11.92%-- 
RVMDRevolution Medicines149.035+2.025+1.38%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Inovio Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer and infectious diseases. INOVIO's platform harnesses the power of in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. Its candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease of the respiratory tract caused by HPV infection. In its completed Phase 1/2 clinical trial of INO-3107 for the treatment of HPV-6 and HPV-11-associated RRP.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.